The agency gave Akebia’s drug an OK after receiving more safety data, but imposed a strict boxed warning for its use that may limit uptake.
Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to ...
In 2022, NeuGen informed MassMutual they were laying off 110 employees. According to the suit, MassMutual declared a total termination of the Agreement and gave the Fund to the Plan participants at ...
Bristol-Myers Squibb may be on the value menu for a while as the acquisition strategy may take time to pay off. Read more to ...
Plus: A breakthrough in treating food allergies. All in The Temperature, a weekly newsletter covering climate, health and ...
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow ...